الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 110 |  |  |
| | | from | 110 | | |
Abstract
The impact of off-pump coronary artery bypass (OPCAB) surgery on the patient outcome, as judged by the end-points of mortality and morbidity, is still debated. However, if compared with on-pump revascularization, OPCAB surgery shows a slight trend towards fewer cardiac events for up to 3 years of follow-up.
Recently, the international CABG Off or On Pump Revascularization Study (CORONARY) showed no significant treatment-related differences between off-pump and on-pump CABG with regard to any 5-year outcomes.
Dex can maintain a stable hemodynamic status during coronary artery bypass graft (CABG) surgery, and is a safe substitution for propofol.
In this study we assessed the effect of dexmedetomidine infusion as an adjuvant to general anesthesia in off-pump coronary artery bypass grafting by using the TEE.
The study was performed on 36 patients divided equally in two groups: One group received dexmedetomidine, and the other group received the same volume of normal saline. both group shared the same preoperative demographic data.
both groups were well matched regarding the demographic data (e.g. age, sex and BMI) and clinical (ASA physical status, co-morbidities and number of diseased vessels to be operated) characteristics.
There was no significant difference between the two groups regarding the preoperative, and intra operative hemodynamics changes (HR, systolic, diastolic, and mean arterial BP).